Dr. Masarova is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
1515 Holcombe Blvd
0428
Houston, TX 77030Phone+1 832-750-4211- Is this information wrong?
Education & Training
- Comenius UniversityClass of 2007
Certifications & Licensure
- FL State Medical License 2021 - Present
- TX State Medical License 2018 - 2026
- OK State Medical License 2020 - 2021
Clinical Trials
Publications & Presentations
PubMed
- 38 citationsAzacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: phase 1 results of a single-centre, dose-escalati...Alexandre Bazinet, Faezeh Darbaniyan, Elias Jabbour, Guillermo Montalban-Bravo, Maro Ohanian
The Lancet. Haematology. 2022-10-01 - 9 citationsPhase II study of single-agent nivolumab in patients with myelofibrosisIman Abou Dalle, Hagop M. Kantarjian, Naval Daver, Lucia Masarova, Naveen Pemmaraju
Annals of Hematology. 2021-08-05 - 145 citationsVenetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid LeukemiaCourtney D. DiNardo, Curtis Lachowiez, Koichi Takahashi, Sanam Loghavi, Lianchun Xiao
Journal of Clinical Oncology. 2021-05-27
Abstracts/Posters
- Azacitidine (AZA) with Nivolumab (Nivo), and AZA with Nivo + Ipilimumab (Ipi) in Relapsed/Refractory Acute Myeloid Leukemia: A Non-Randomized, Prospective, Phase 2 StudyLucia Masarova, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Ten-Day Decitabine with Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia: Updated Results of a Phase II TrialClinically Relevant AbstractLucia Masarova, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Outcomes of Relapsed or Refractory Acute Myeloid Leukemia after Frontline Hypomethylating Agent with Venetoclax RegimensLucia Masarova, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Join now to see all
Lectures
- Phase 2 Study of Ruxolitinib (RUX) in Combination with 5-Azacitidine (AZA) in Patients (pts) with Myelofibrosis61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Efficacy and Safety of Pomalidomide in Combination with Prednisone in Patients with Myelofibrosis and Anemia – Final Results of a Prospective Phase 2 Study2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Prognostic Impact of Activating Mutations of the NRAS/KRAS Genes in Patients with Primary and Post-Essential Thrombocythemia (ET)/Polycythemia Vera (PV) Myelofibrosis ...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Join now to see all
Press Mentions
- Ruxolitinib plus Azacitidine Improves Survival, Bone Marrow Fibrosis in MyelofibrosisNovember 13th, 2018
Professional Memberships
- Member
Hospital Affiliations
- University of Texas M.D. Anderson Cancer CenterHouston, Texas
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: